Iversun: Advanced Ivermectin Therapy for Parasitic Infections
Iversun
| Product dosage: 12mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 100 | $2.50 | $250.00 (0%) | 🛒 Add to cart |
| 200 | $1.75 | $500.00 $350.00 (30%) | 🛒 Add to cart |
| 300 | $1.67
Best per pill | $750.00 $500.00 (33%) | 🛒 Add to cart |
Synonyms | |||
Similar products
Iversun represents a significant advancement in antiparasitic therapy, offering targeted treatment for a range of parasitic infections with a well-established efficacy and safety profile. This prescription medication contains ivermectin, a potent antiparasitic agent that works by binding to glutamate-gated chloride ion channels in invertebrate nerve and muscle cells, leading to increased cell permeability and paralysis of target parasites. Developed through rigorous pharmaceutical research, Iversun is formulated to provide reliable parasiticidal activity against nematodes and ectoparasites while maintaining favorable pharmacokinetic properties. Its mechanism of action demonstrates selective toxicity to parasites while having minimal effect on human hosts due to the absence of glutamate-gated chloride channels in mammalian nervous systems. Medical professionals prescribe Iversun for both community-based treatment programs and individual clinical cases where parasitic infections require systematic intervention.
Features
- Contains ivermectin as the active pharmaceutical ingredient
- Available in 3mg scored tablets for precise dosing
- Standardized formulation ensuring consistent bioavailability
- Manufactured under strict GMP (Good Manufacturing Practice) guidelines
- Temperature-stable composition requiring no special handling
- Child-resistant packaging for safety
- Batch-traceable production with quality control documentation
- Vegan-friendly excipients without animal-derived components
Benefits
- Effectively eliminates target parasites within 24-48 hours of administration
- Reduces transmission rates in endemic areas through community treatment programs
- Provides single-dose efficacy for many parasitic infections
- Minimizes risk of developing resistance when used according to guidelines
- Improves nutritional status and overall health by clearing parasitic burdens
- Supports public health initiatives for disease control and elimination
Common use
Iversun is primarily indicated for the treatment of strongyloidiasis caused by the nematode Strongyloides stercoralis and for the treatment of onchocerciasis (river blindness) caused by the filarial worm Onchocerca volvulus. It is also used off-label for certain other parasitic infections including scabies caused by Sarcoptes scabiei, cutaneous larva migrans, and head lice infestations. In mass drug administration programs, Iversun is distributed in endemic communities to control and eventually eliminate transmission of onchocerciasis and lymphatic filariasis when combined with other antiparasitic agents. Medical practitioners may also prescribe Iversun for compassionate use in cases of difficult-to-treat parasitic infections where standard therapies have proven ineffective.
Dosage and direction
Dosage is based on body weight and must be determined by a healthcare professional. For strongyloidiasis: 200 mcg/kg orally as a single dose. For onchocerciasis: 150 mcg/kg orally as a single dose, repeated every 6-12 months until asymptomatic. Tablets should be taken with a full glass of water on an empty stomach, at least 1 hour before or 2 hours after food to maximize absorption. The scored tablets allow for accurate dosing adjustments. For patients unable to swallow tablets whole, tablets may be crushed and mixed with a small amount of water immediately before administration. Follow-up stool examinations or skin snip tests are recommended to confirm parasite clearance.
Precautions
Patients should be screened for concomitant loiasis (Loa loa infection) before administration, as severe encephalopathic reactions have occurred in patients with high microfilarial loads. Use with caution in elderly patients and those with hepatic impairment, although dosage adjustment is typically not required. Breastfeeding should be interrupted for 72 hours after administration due to secretion in milk. Patients should be advised that temporary worsening of itching, rash, or fever may occur during the first few days of treatment as parasites die (Mazzotti-like reaction). Those with asthma may experience exacerbation of symptoms during treatment.
Contraindications
Iversun is contraindicated in patients with known hypersensitivity to ivermectin or any component of the formulation. It should not be administered to children weighing less than 15 kg unless specifically indicated and under direct medical supervision. Contraindicated in patients with meningitis or other conditions that may increase the permeability of the blood-brain barrier. Should not be used during pregnancy unless the potential benefit justifies the potential risk to the fetus (Pregnancy Category C).
Possible side effect
Common side effects (≥1% of patients) include dizziness, pruritus, rash, fever, and lymph node tenderness. Less frequent side effects (0.1-1%) may include orthostatic hypotension, diarrhea, nausea, vomiting, and transient eosinophilia. Rare adverse reactions (<0.1%) include elevated liver enzymes, tachycardia, visual disturbances, and edema. Severe reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and encephalopathy have been reported in exceptional cases, particularly in patients with high parasite burdens.
Drug interaction
Iversun may interact with other medications that affect P-glycoprotein transporters, such as cyclosporine, which could increase ivermectin plasma concentrations. Concurrent use with benzodiazepines or barbiturates may potentiate central nervous system depression. Warfarin levels may be affected, requiring closer monitoring of coagulation parameters. Anticonvulsants such as valproic acid and phenytoin may decrease ivermectin levels. Alcohol consumption should be avoided during treatment due to potential additive effects on neurological function.
Missed dose
If a dose is missed, it should be taken as soon as remembered unless it is almost time for the next scheduled dose. In that case, skip the missed dose and resume the regular dosing schedule. Do not double the dose to make up for a missed administration. For mass drug administration programs with annual or semi-annual dosing, contact healthcare providers for guidance on rescheduling missed treatments.
Overdose
Symptoms of overdose may include exaggerated pharmacological effects including severe dizziness, nausea, vomiting, and pupillary dilation. In massive overdose, CNS depression including ataxia, respiratory depression, and coma may occur. There is no specific antidote for ivermectin overdose. Treatment is supportive and symptomatic, including gastric lavage if ingestion was recent and activated charcoal to prevent further absorption. Maintain adequate airway and ventilation, and monitor vital signs closely. Hemodialysis is not effective due to high protein binding.
Storage
Store at controlled room temperature between 15-30°C (59-86°F). Keep in the original container, tightly closed, and protected from moisture and light. Do not freeze. Keep out of reach of children and pets. Discard any unused medication after the expiration date printed on the packaging. Do not flush medications down the toilet or pour down a drain unless instructed to do so.
Disclaimer
This information is provided for educational purposes only and does not replace professional medical advice. Always consult with a qualified healthcare provider before starting any new medication. The prescribing physician should be aware of the complete medical history of the patient before administering Iversun. Actual product packaging and inserts may contain different or additional information.
Reviews
Clinical studies have demonstrated that Iversun achieves parasite clearance rates of 85-95% for strongyloidiasis with a single dose. In onchocerciasis control programs, community-wide treatment with Iversun has reduced microfilarial loads by over 90% after several rounds of treatment. Dermatologists report excellent efficacy in crusted scabies cases when used as part of combination therapy. Patients describe significant improvement in quality of life measures following treatment, particularly reduction in chronic itching and skin manifestations. Healthcare workers in endemic areas note the convenience of single-dose administration for mass treatment campaigns. Long-term safety data from decades of use support its favorable risk-benefit profile when used appropriately.